Literature DB >> 15302161

Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies.

Melissa M Damschroder1, Alexander A Kozhich, Robert M Woods, Li Cheng, Brian A Mullikin, Susan D Wilson, Nancy D Ulbrandt, Christine M Bachy, Herren Wu, JoAnn A Suzich, Peter A Kiener, William F Dall'Acqua, Wendy I White.   

Abstract

A panel of anti-human CD2 monoclonal antibodies (mAb) and soluble human CD58 (LFA-3) were tested for binding to human peripheral blood mononuclear cells (PBMCs), recombinant human CD2 and mononuclear cells from Cynomolgus, Rhesus and African green monkey, Stump-tail, Pig-tail and Assamese macaque, Chimpanzee and Baboon. This analysis revealed that whilst some antibodies recognized all species, there were differential binding profiles with others. Three antibodies, MEDI-507, 6F10.3 and 4B2, recognized CD2 from human and Chimpanzee but not that from the other primates. We have cloned eight of the previously unknown primate CD2 molecules and report here their sequences for the first time. This analysis revealed that 12 amino acids formed a common set of residues in the extra cellular domain of human and Chimpanzee CD2. Using a "knock-in" mutagenesis approach starting with Baboon CD2, which does not bind MEDI-507, 6F10.3 and 4B2, we have identified three residues in the adhesion domain of human CD2 which are critical for its binding to these mAbs. These residues, N18, K55 and T59 define a region located outside of the previously described binding regions on CD2. Affinity measurements of the mutants revealed a variety of degrees of binding restoration for MEDI-507, 6F10.3 and 4B2, indicating that there are fine differences within a given epitope. Furthermore, the analysis of the competition of several of the anti-human CD2 antibodies with each other and CD58 demonstrated the existence of a continuum of overlapping epitopes on human CD2, which is in contrast to the commonly held belief that epitopes on human CD2 are clearly segregated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302161     DOI: 10.1016/j.molimm.2004.05.004

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  5 in total

1.  Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro.

Authors:  Manuel A Podestà; Christian Binder; Felix Sellberg; Susan DeWolf; Brittany Shonts; Siu-Hong Ho; Aleksandar Obradovic; Elizabeth Waffarn; Nichole Danzl; David Berglund; Megan Sykes
Journal:  Am J Transplant       Date:  2019-08-13       Impact factor: 9.369

2.  Bovine CD2-/NKp46+ cells are fully functional natural killer cells with a high activation status.

Authors:  Preben Boysen; Ingrid Olsen; Ingvild Berg; Siri Kulberg; Grethe M Johansen; Anne K Storset
Journal:  BMC Immunol       Date:  2006-04-27       Impact factor: 3.615

Review 3.  CD2 Immunobiology.

Authors:  Christian Binder; Filip Cvetkovski; Felix Sellberg; Stefan Berg; Horacio Paternina Visbal; David H Sachs; Erik Berglund; David Berglund
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

4.  Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity.

Authors:  Christian Binder; Felix Sellberg; Filip Cvetkovski; Stefan Berg; Erik Berglund; David Berglund
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

5.  Safety and pharmacodynamics of anti-CD2 monoclonal antibody treatment in cynomolgus macaques - an experimental study.

Authors:  Erik Berglund; Paula Alonso-Guallart; Makenzie Danton; Felix Sellberg; Christian Binder; Robin Fröbom; David Berglund; Nathaly Llore; Hiroshi Sakai; Alina Iuga; Dilrukshi Ekanayake-Alper; Keith A Reimann; David H Sachs; Megan Sykes; Adam Griesemer
Journal:  Transpl Int       Date:  2019-11-15       Impact factor: 3.842

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.